760 related articles for article (PubMed ID: 34396154)
1. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
Boekel L; Steenhuis M; Hooijberg F; Besten YR; van Kempen ZLE; Kummer LY; van Dam KPJ; Stalman EW; Vogelzang EH; Cristianawati O; Keijzer S; Vidarsson G; Voskuyl AE; Wieske L; Eftimov F; van Vollenhoven R; Kuijpers TW; van Ham SM; Tas SW; Killestein J; Boers M; Nurmohamed MT; Rispens T; Wolbink G
Lancet Rheumatol; 2021 Nov; 3(11):e778-e788. PubMed ID: 34396154
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Boekel L; Stalman EW; Wieske L; Hooijberg F; van Dam KPJ; Besten YR; Kummer LYL; Steenhuis M; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Vogelzang EH; Leeuw M; Atiqi S; van Vollenhoven R; Gerritsen M; van der Horst-Bruinsma IE; Lems WF; Nurmohamed MT; Boers M; Keijzer S; Keijser J; van de Sandt C; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Kuijpers TW; Wolbink G; Eftimov F;
Lancet Rheumatol; 2022 Jun; 4(6):e417-e429. PubMed ID: 35527808
[TBL] [Abstract][Full Text] [Related]
3. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
4. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.
Wieske L; van Dam KPJ; Steenhuis M; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Kuijpers TW; Rispens T; Eftimov F;
Lancet Rheumatol; 2022 May; 4(5):e338-e350. PubMed ID: 35317410
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
6. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.
Aikawa NE; Kupa LVK; Pasoto SG; Medeiros-Ribeiro AC; Yuki EFN; Saad CGS; Pedrosa T; Fuller R; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Pereira RMR; Seguro LPC; Valim JML; Waridel F; Sartori AMC; Duarte AJS; Antonangelo L; Sabino EC; Menezes PR; Kallas EG; Silva CA; Bonfa E
Lancet Rheumatol; 2022 Feb; 4(2):e113-e124. PubMed ID: 34901885
[TBL] [Abstract][Full Text] [Related]
8. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
Oosting SF; van der Veldt AAM; GeurtsvanKessel CH; Fehrmann RSN; van Binnendijk RS; Dingemans AC; Smit EF; Hiltermann TJN; den Hartog G; Jalving M; Westphal TT; Bhattacharya A; van der Heiden M; Rimmelzwaan GF; Kvistborg P; Blank CU; Koopmans MPG; Huckriede ALW; van Els CACM; Rots NY; van Baarle D; Haanen JBAG; de Vries EGE
Lancet Oncol; 2021 Dec; 22(12):1681-1691. PubMed ID: 34767759
[TBL] [Abstract][Full Text] [Related]
9. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands.
Boekel L; Atiqi S; Leeuw M; Hooijberg F; Besten YR; Wartena R; Steenhuis M; Vogelzang E; Webers C; Boonen A; Gerritsen M; Lems WF; Tas SW; van Vollenhoven RF; Voskuyl AE; van der Horst-Bruinsma I; Nurmohamed M; Rispens T; Wolbink G
Lancet Rheumatol; 2023 Jul; 5(7):e375-e385. PubMed ID: 37398978
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort.
Zecca E; Rizzi M; Tonello S; Matino E; Costanzo M; Rizzi E; Casciaro GF; Manfredi GF; Acquaviva A; Gagliardi I; Calzaducca E; Mallela VR; D'Onghia D; Minisini R; Bellan M; Castello LM; Gavelli F; Avanzi GC; Patrucco F; Chiocchetti A; Pirisi M; Rigamonti C; Lilleri D; Sola D; Sainaghi PP
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016388
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
[TBL] [Abstract][Full Text] [Related]
14. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
[TBL] [Abstract][Full Text] [Related]
16. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.
Pearce FA; Lim SH; Bythell M; Lanyon P; Hogg R; Taylor A; Powter G; Cooke GS; Ward H; Chilcot J; Thomas H; Mumford L; McAdoo SP; Pettigrew GJ; Lightstone L; Willicombe M
Lancet Rheumatol; 2023 Aug; 5(8):e461-e473. PubMed ID: 38251578
[TBL] [Abstract][Full Text] [Related]
17. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
Mahil SK; Bechman K; Raharja A; Domingo-Vila C; Baudry D; Brown MA; Cope AP; Dasandi T; Graham C; Khan H; Lechmere T; Malim MH; Meynell F; Pollock E; Sychowska K; Barker JN; Norton S; Galloway JB; Doores KJ; Tree T; Smith CH
Lancet Rheumatol; 2022 Jan; 4(1):e42-e52. PubMed ID: 34778846
[TBL] [Abstract][Full Text] [Related]
18. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis.
Martin CA; Nazareth J; Jarkhi A; Pan D; Das M; Logan N; Scott S; Bryant L; Abeywickrama N; Adeoye O; Ahmed A; Asif A; Bandi S; George N; Gohar M; Gray LJ; Kaszuba R; Mangwani J; Martin M; Moorthy A; Renals V; Teece L; Vail D; Khunti K; Moss P; Tattersall A; Hallis B; Otter AD; Rowe C; Willett BJ; Haldar P; Cooper A; Pareek M
EClinicalMedicine; 2023 Apr; 58():101926. PubMed ID: 37034357
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
20. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.
Bjørlykke KH; Ørbo HS; Tveter AT; Jyssum I; Sexton J; Tran TT; Christensen IE; Kro GB; Kvien TK; Jahnsen J; Munthe LA; Chopra A; Warren DJ; Mjaaland S; Haavardsholm EA; Grødeland G; Provan SA; Vaage JT; Syversen SW; Goll GL; Jørgensen KK
Lancet Rheumatol; 2023 Jan; 5(1):e36-e46. PubMed ID: 36415604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
